News, views and contacts from the global Pharmaceutical industry
 

News Archive

Archive of industry news from the global pharmaceutical industry

News By Date

July 2014

Top

AstraZeneca to have rights of Almirall’s respiratory franchise
31 July 2014 Spain-based Almirall and AstraZeneca have entered into an agreement, involving Almirall transfering the rights to its respiratory franchise to Astrazeneca for an initial consideration of $875m...

FDA approves Bayer’s Eylea to treat diabetic macular edema
31 July 2014 Bayer has announced the US Food and Drug Administration’s (FDA) approval of Eylea, an aflibercept solution for injection into the eye for the treatment of diabetic macular edema...

European Commission approves Eliquis for deep vein thrombosis and pulmonary embolism
30 July 2014 Bristol-Myers Squibb and Pfizer have announced the European Commission’s approval of Eliquis, an oral selective Factor Xa inhibitor, to treat deep vein thrombosis (DVT) and pulmonary embolism...

EMA committee recommends approval of Gilead Sciences’ Zydelig
30 July 2014 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Gilead Sciences’ marketing authorisation application for Zydelig...

Burnet and ARTES partner to develop new vaccine for malaria
29 July 2014 Australia's largest virology and communicable disease research centre Burnet Institute has partnered with ARTES Biotechnology to develop a new vaccine to treat...

CHMP recommends Pharmacyclics’ Imbruvica to treat two blood cancers
28 July 2014 The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the full marketing approval of Pharmacyclics' Imbruvica (ibrutinib) in the EU...

FDA grants orphan drug designation to Clementia Pharmaceuticals’ palovarotene
28 July 2014 Clinical stage biopharmaceutical company Clementia Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its palovarotene to treat...

EMA accepts Alexion’s marketing authorisation application for hypophosphatasia therapy
25 July 2014 Alexion Pharmaceuticals has announced that the European Medicines Agency (EMA) has validated and granted accelerated assessment for its marketing authorisation application for asfotase alfa...

FDA approves Gilead Sciences’ Zydelig for three types of blood cancers
25 July 2014 Gilead Sciences has obtained US Food and Drug Administration (FDA) approval for its Zydelig (idelalisib) 150mg tablets for treatment of three B-cell blood...

Neurotrope and Mount Sinai collaborate to develop Bryostatin-1 for NPC disease
24 July 2014 Neurotrope Bioscience has entered into a collaboration agreement with Icahn School of Medicine at Mount Sinai to develop Bryostatin-1 in the treatment of Niemann-Pick Type C (NPC) disease....

NICE recommends Sucampo’s Amitiza for chronic idiopathic constipation treatment
24 July 2014 The UK National Institute of Health and Care Excellence (NICE) has recommended Sucampo Pharmaceuticals' Amitiza (lubiprostone) as a treatment option for chronic idiopathic constipation (CIC)...

UK researchers to gain access to deprioritised pharmaceutical compounds
23 July 2014 UK Business Secretary Vince Cable has announced a new partnership between the Medical Research Council (MRC) and seven global pharmaceutical companies, which will give researchers access to...

Sage Therapeutics receives fast track designation for status epilepticus therapy
23 July 2014 Ligand Pharmaceuticals has announced that its partner Sage Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for the Captisol-enabled SAGE-547 to...

Aduro’s pancreatic cancer immunotherapy gets FDA breakthrough therapy designation
22 July 2014 The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Aduro BioTech's pancreatic cancer combination treatment that consists of its CRS-207 and GVAX...

Shire acquisition could save AbbVie $8bn tax on Humira over 15 years, says GlobalData
22 July 2014 AbbVie's relocation to Ireland following the acquisition of Shire for $54bn is expected to reduce the annual tax expense for the company by more than 7%, according to research and consulting...

Salix Pharmaceuticals and Pharming receive FDA approval for Ruconest
21 July 2014 Salix Pharmaceuticals and Pharming have announced US Food and Drug Administration (FDA) approval of Ruconest for treatment of acute angioedema attacks in adult and adolescent patients...

CTI BioPharma receives Israeli approval for aggressive B-cell non-Hodgkin's lymphoma therapy
21 July 2014 CTI BioPharma has obtained Israeli Ministry of Health's approval for Pixuvri (pixantrone), as a monotherapy to treat adult patients with multiply relapsed or refractory aggressive...

Pfizer to acquire InnoPharma for $360m
18 July 2014 Pfizer has entered into an agreement to acquire US-based pharmaceutical development company InnoPharma for...

FDA Grants breakthough therapy designation for InterMune’s pirfenidone
18 July 2014 InterMune has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its pirfenidone, an investigational treatment for adult patients with idiopathic...

FDA approves Octapharma’s immune thrombocytopenic purpura therapy
17 July 2014 The US Food and Drug Administration (FDA) has approved Octapharma USA's Octagam 10% for treatment of adults with chronic immune thrombocytopenic purpura (ITP), a platelet disorder that can...

Medical Research Council to lead initiative to tackle antimicrobial resistance
17 July 2014 The UK Medical Research Council (MRC) will lead a cross-council initiative to tackle antimicrobial resistance (AMR) in all...